CytomX Therapeutics (CTMX) to Release Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.14) per share and revenue of $4.6820 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. On average, analysts expect CytomX Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $4.08 on Wednesday. CytomX Therapeutics has a one year low of $0.90 and a one year high of $8.21. The company’s 50 day moving average price is $4.72 and its 200 day moving average price is $4.52. The firm has a market capitalization of $694.38 million, a price-to-earnings ratio of -102.00 and a beta of 2.18.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald lifted their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Wedbush lifted their target price on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Jefferies Financial Group lifted their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Barclays lifted their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Finally, JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $7.00 to $12.00 in a research note on Monday, March 16th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.44.

Insider Activity at CytomX Therapeutics

In other CytomX Therapeutics news, CFO Christopher Ogden sold 19,323 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $124,053.66. Following the sale, the chief financial officer directly owned 296,948 shares in the company, valued at approximately $1,906,406.16. The trade was a 6.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean A. Mccarthy sold 118,969 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $763,780.98. Following the sale, the chief executive officer owned 1,078,922 shares in the company, valued at approximately $6,926,679.24. The trade was a 9.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 191,063 shares of company stock valued at $1,226,624 in the last ninety days. Company insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN grew its stake in shares of CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,000 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter valued at approximately $52,000. Bank of Nova Scotia bought a new stake in shares of CytomX Therapeutics in the 4th quarter valued at approximately $58,000. Invesco Ltd. bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at approximately $32,000. Finally, Paces Ferry Wealth Advisors LLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter valued at approximately $63,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.